<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of exogenous endophthalmitis due to Candida species</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of exogenous endophthalmitis due to Candida species</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of exogenous endophthalmitis due to Candida species</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marlene L Durand, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer E Thorne, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H866067736"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Candida</em> species are a common cause of fungal endophthalmitis. This infection arises in two discrete ways:</p><p class="bulletIndent1"><span class="glyph">●</span>The exogenous form follows trauma, eye surgery, or progression of fungal keratitis (corneal infection). Fungi are directly inoculated into the aqueous and/or vitreous.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The endogenous form follows candidemia, with hematogenous seeding of the eye. Fungi usually first seed the highly vascular choroid, then infection typically progresses through the retina into the vitreous. The aqueous is sometimes involved as well. (See  <a class="medical medical_review" href="/z/d/html/2446.html" rel="external">"Treatment of endogenous endophthalmitis and chorioretinitis due to Candida species"</a>.)</p><p></p><p>The treatment of exogenous <em>Candida</em> endophthalmitis will be reviewed here. The epidemiology, pathogenesis, clinical manifestations, and diagnosis of fungal endophthalmitis are discussed separately. The treatment of endogenous endophthalmitis caused by <em>Candida</em> species and endophthalmitis due to molds are also presented separately. Bacterial endophthalmitis and <em>Fusarium</em> keratitis as well as candidemia and other types of <em>Candida</em> infection are also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16953.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis"</a> and  <a class="medical medical_review" href="/z/d/html/2446.html" rel="external">"Treatment of endogenous endophthalmitis and chorioretinitis due to Candida species"</a> and  <a class="medical medical_review" href="/z/d/html/16205.html" rel="external">"Treatment of endophthalmitis due to molds"</a> and  <a class="medical medical_review" href="/z/d/html/3418.html" rel="external">"Bacterial endophthalmitis"</a> and  <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2416.html" rel="external">"Overview of Candida infections"</a> and  <a class="medical medical_review" href="/z/d/html/15674.html" rel="external">"Treatment and prevention of Fusarium infection"</a>.)</p><p class="headingAnchor" id="H866067796"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>The term "endophthalmitis" means infection involving the vitreous and/or aqueous humors  (<a class="graphic graphic_figure graphicRef57690" href="/z/d/graphic/57690.html" rel="external">figure 1</a>). Exogenous endophthalmitis signifies that the infection was introduced into the eye from the "outside," either by trauma, eye surgery, or extension of corneal infection (keratitis).</p><p class="headingAnchor" id="H866068119"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Exogenous endophthalmitis is treated with an intraocular injection of an antimicrobial agent into the vitreous. An intracameral injection (into the aqueous) may be given in cases with significant anterior segment infection. A vitrectomy (surgical debridement of the vitreous) may be performed in cases with significant vitritis or that fail to improve with intravitreal injections. Surgical removal of any foreign material (eg, artificial intraocular lens) may be necessary. Adjunctive systemic antifungal therapy is given in most cases. </p><p>Our recommendations are generally in keeping with the 2016 Infectious Diseases Society of America (IDSA) guidelines for the management of candidiasis [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H1068616348"><span class="h2">Approach to treatment</span></p><p class="headingAnchor" id="H3297786872"><span class="h3">Exogenous endophthalmitis with vitritis</span><span class="headingEndMark"> — </span>We suggest the following treatment course:</p><p class="bulletIndent1"><span class="glyph">●</span>Vitrectomy (when there is significant vitritis or failure to improve with intravitreal injections alone) <strong>and</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravitreal injection of <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (5 or 10 mcg in 0.1 mL sterile water) or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> (100 mcg in 0.1 mL sterile water or normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) <strong>and</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic antifungal therapy</strong> – For <em>Candida</em> species that are susceptible to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> and <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, systemic therapy with oral fluconazole (800 mg [12 mg/kg] loading dose, then 400 to 800 mg [6 to 12 mg/kg] orally daily) or voriconazole (400 mg [6 mg/kg] intravenously [IV] every 12 hours for two doses, then 200 to 300 mg [3 to 4mg/kg] IV or orally every 12 hours) can be used. For fluconazole-susceptible isolates, fluconazole is preferred over voriconazole.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most patients infected with a fluconazole-resistant species can be treated with systemic <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, as discussed below:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For <em>C. krusei</em>, which is inherently resistant to <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> and susceptible to <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> (nearly all cases), voriconazole should be used.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For <em>C. glabrata</em> isolates that are <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> resistant, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> should be used if the isolate is shown to be susceptible. It is important to note that cross-resistance between fluconazole and voriconazole is common among <em>C. glabrata</em> isolates, and patients infected with this species should be followed carefully for their response to treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who present acutely, the IV formulation of <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> is recommended initially prior to switching to oral therapy. Oral therapy at a dose of 200 to 300 mg orally twice daily can be used following an initial response to the IV formulation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with a subacute presentation who are being managed as outpatients, the <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> loading dose can be given orally (400 mg [6 mg/kg] twice a day for two doses), followed by an oral maintenance dose of 200 to 300 mg (3 to 4 mg/kg) twice daily.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>It is important to measure serum trough concentrations of <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> four to seven days after initiating therapy to ensure that adequate concentrations have been achieved to allow success and to avoid high levels that have been associated with adverse events. Although debate remains over the optimal target concentration, available data suggest a therapeutic range between 2 and 5 mg/L. In patients with concentrations that are too high or too low, the serum concentration should be rechecked four to five days after adjusting the dose. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Voriconazole'</a>.)</p><p></p><p>For patients who have an IOL who fail to improve after the therapeutic regimen described above (vitrectomy, intravitreal amphotericin B or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> injection, and systemic azole therapy), the IOL will likely need to be removed, and repeat intravitreal injections of <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (5 mcg in 0.1 mL sterile water) or voriconazole (100 mcg in 0.1 mL sterile water or normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) given.</p><p class="headingAnchor" id="H143248736"><span class="h3">Exogenous endophthalmitis with primarily aqueous involvement</span><span class="headingEndMark"> — </span>In cases of exogenous <em>Candida</em> endophthalmitis in which the aqueous is the major site of intraocular infection (eg, from contiguous spread of fungal keratitis), intracameral (into the anterior chamber) injection of <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> (50 mcg in 0.1 mL of sterile water) should be administered. Intracameral <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (5 mcg in 0.1 mL sterile water) may be given instead of intracameral voriconazole for voriconazole-resistant strains of <em>Candida</em>. Even in cases in which only the aqueous appears to be involved clinically, intravitreal injection of amphotericin B deoxycholate (5 or 10 mcg in 0.1 mL sterile water) or voriconazole (100 mcg in 0.1 mL sterile water or normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) should be considered. Such cases may have occult infection of the vitreous. Repeated intracameral or intravitreal injections may be given, usually separated by at least two days. The necessity and timing of repeat injections is determined by the ophthalmologist based on the eye's response to therapy.</p><p>If concurrent keratitis is present, topical antifungal agents (topical <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> 1% or topical <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> 0.15% in sterile water) should be given. Topical voriconazole penetrates the cornea and can achieve therapeutic levels in the aqueous [<a href="#rid2">2</a>], so the addition of frequent topical voriconazole eyedrops (in addition to intracameral and systemic therapy) may be beneficial in treating aqueous infections due to voriconazole-susceptible strains of <em>Candida</em>. Corneal transplantation is sometimes required to control a fungal keratitis that has extended into the aqueous.</p><p>In addition to intracameral antifungal therapy, systemic <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> or <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> should be given for susceptible strains, even for cases in which only the aqueous is involved. Dosing is discussed above. (See <a class="local">'Exogenous endophthalmitis with vitritis'</a> above.)</p><p>The management of endogenous endophthalmitis caused by <em>Candida</em> species and endophthalmitis caused by molds are presented separately. (See  <a class="medical medical_review" href="/z/d/html/2446.html" rel="external">"Treatment of endogenous endophthalmitis and chorioretinitis due to Candida species", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/16205.html" rel="external">"Treatment of endophthalmitis due to molds", section on 'Treatment Modalities'</a>.)</p><p class="headingAnchor" id="H1842267548"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>The optimal duration of antifungal therapy for exogenous <em>Candida</em> endophthalmitis is unknown but is typically several weeks, depending on resolution of lesions as determined by serial ophthalmic examinations [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H728946907"><span class="h2">Intraocular therapy</span><span class="headingEndMark"> — </span>In cases in which the aqueous is primarily involved (eg, acute <em>Candida</em> endophthalmitis after corneal transplantation), either <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> may be injected intracamerally (into the anterior chamber)  (<a class="graphic graphic_figure graphicRef57690" href="/z/d/graphic/57690.html" rel="external">figure 1</a>). Intracameral injection of amphotericin B deoxycholate has been used for many years for fungal endophthalmitis [<a href="#rid3">3</a>] and appears to be effective [<a href="#rid4">4,5</a>]. The usual dose of amphotericin B deoxycholate for intracameral use is 5 mcg in 0.1 mL sterile water. There may be transient increase in eye pain, hypopyon, or intra-aqueous inflammation in some eyes after amphotericin B injection, but this resolves by 24 to 48 hours [<a href="#rid4">4,5</a>]. Several studies have reported effective use of intracameral voriconazole at doses ranging from 12.5 mcg to 100 mcg per 0.1 mL [<a href="#rid6">6-8</a>]. Intracameral doses of 100 mcg of voriconazole have been used repeatedly in some eyes without any apparent toxicity [<a href="#rid7">7</a>], but we prefer a dose of 50 mcg due to the limited experience with intracameral voriconazole and because this dose produces sufficiently high levels in the aqueous to treat <em>Candida</em> species.</p><p>Once the infection is known to be due to <em>Candida</em> spp, we prefer to use intracameral <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> rather than <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>, given the potential toxicity of the latter agent. However, in cases in which rapid improvement does not occur with voriconazole, we favor switching to amphotericin B deoxycholate. Efficacy studies comparing intracameral administration of these two agents have not been performed.</p><p>Intracameral <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> has been shown to have a half-life of only 22 minutes in an experimental rabbit model [<a href="#rid9">9</a>], so topical voriconazole 1% solution can be used to prolong the drug level in the aqueous. Application of 1% voriconazole ophthalmic solution (eyedrops) every 2 hours for 24 hours prior to scheduled eye surgery produced high levels in the aqueous in one study of 13 patients [<a href="#rid10">10</a>]. In cases of exogenous <em>Candida</em> endophthalmitis resulting from <em>Candida </em>keratitis, the keratitis should also be treated with antifungal eyedrops. Topical voriconazole eyedrops (1%) are preferred in these cases since topical voriconazole penetrates the cornea and achieves good levels in the aqueous, whereas topical amphotericin B does not.</p><p>It is important to note that intracameral injections of <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> or <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> do <strong>not</strong> produce significant levels in the vitreous, so intravitreal injections of voriconazole or amphotericin B deoxycholate should also be given in any case of exogenous endophthalmitis if vitreous involvement cannot be excluded [<a href="#rid11">11</a>].</p><p>Therapy should include vitrectomy and intravitreal injection of an antifungal agent when the vitreous shows severe involvement. Vitrectomy entails the use of a vitrector, an instrument inserted into the vitreous that simultaneously cuts and aspirates much of the 4 mL of gel-like vitreous into a canister  (<a class="graphic graphic_figure graphicRef59512" href="/z/d/graphic/59512.html" rel="external">figure 2</a>). Intravitreal <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (5 or 10 mcg in 0.1 mL sterile water) or intravitreal <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> (100 mcg in 0.1 mL sterile water or normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) may be used, the latter only for voriconazole-susceptible isolates. Most <em>Candida</em> species are susceptible to voriconazole, however [<a href="#rid12">12</a>].</p><p>When infection has resulted from cataract surgery with IOL implantation, it is often necessary to remove the IOL. <em>Candida</em> may produce a chronic inflammation in the aqueous after cataract surgery, with symptoms persisting for months and misdiagnosed as a noninfectious anterior uveitis; cure nearly always requires removal of the IOL in these cases in addition to other antifungal therapy [<a href="#rid13">13</a>]. Antifungal drugs can suppress but cannot always cure the infection without removal of the IOL. This is likely related to the development of a biofilm, which some <em>Candida</em> species readily form on the implant. When antifungal agents are stopped in cases in which the IOL is left in place, relapse is a possibility [<a href="#rid14">14</a>].</p><p>If endophthalmitis has followed corneal transplantation with an infected donor cornea, repeat transplantation, along with intracameral <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> or <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a>, is usually indicated at the onset of endophthalmitis.</p><p class="headingAnchor" id="H61418186"><span class="h2">Systemic antifungal therapy</span><span class="headingEndMark"> — </span>In addition to intraocular therapy, we recommend systemic azole therapy, based on the efficacy of systemic azoles in treating endogenous <em>Candida</em> endophthalmitis. (See  <a class="medical medical_review" href="/z/d/html/2446.html" rel="external">"Treatment of endogenous endophthalmitis and chorioretinitis due to Candida species"</a>.)</p><p>Specific recommendations for systemic antifungal therapy are provided above. (See <a class="local">'Approach to treatment'</a> above.)</p><p><a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">Fluconazole</a> achieves concentrations in the vitreous in humans that are approximately 70 percent of that in the plasma [<a href="#rid15">15,16</a>]. Fluconazole has shown efficacy in a rabbit model of exogenous <em>Candida</em> endophthalmitis [<a href="#rid17">17</a>]. <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">Voriconazole</a> has activity against <em>C. krusei</em> and some fluconazole-resistant <em>C. glabrata</em> as well as other common <em>Candida</em> species, and it achieves adequate levels in the eye [<a href="#rid18">18,19</a>]. Because <em>C. glabrata</em> isolates can demonstrate cross-resistance to both fluconazole and voriconazole, susceptibility testing should be performed, and the response to therapy should be monitored closely. (See  <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a>.)</p><p>We generally do <strong>not</strong> recommend systemic amphotericin B for exogenous <em>Candida</em> endophthalmitis because it achieves poor levels in the aqueous and the vitreous [<a href="#rid20">20</a>] and has known systemic toxicities. The value of systemic echinocandins for treating exogenous <em>Candida</em> endophthalmitis is unknown, but it is unlikely that they would be effective because of the poor intraocular concentrations achieved with these agents.</p><p class="headingAnchor" id="H148502501"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Reports on the outcome of therapy for exogenous <em>Candida</em> endophthalmitis vary from vision restored to normal to light perception only. There are too few cases reported to have a firm idea of outcomes, although one series of 15 patients reported visual acuities of at least 20/60 in one-half of the patients, most of whom did not have the artificial intraocular (IOL) lens removed [<a href="#rid21">21</a>]. A series that included five patients with post-cataract surgery <em>Candida</em> endophthalmitis, all of whom had the IOL removed as part of treatment, reported visual outcomes of 20/50 or better in all patients [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H3668652200"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/104270.html" rel="external">"Society guideline links: Candidiasis"</a>.)</p><p class="headingAnchor" id="H866068501"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of infection</strong> – <em>Candida</em> species are common causes of fungal endophthalmitis, but most cases are endogenous, meaning they develop from hematogenous seeding of the eye during candidemia. Exogenous <em>Candida</em> endophthalmitis, in which <em>Candida</em> is inoculated into the aqueous and/or vitreous via the ocular surface, is less common  (<a class="graphic graphic_figure graphicRef57690" href="/z/d/graphic/57690.html" rel="external">figure 1</a>). Exogenous <em>Candida</em> endophthalmitis occurs most commonly after eye surgery (eg, cataract surgery, corneal transplantation) or penetrating eye trauma but may also occur as an extension of <em>Candida</em> keratitis (corneal infection). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Patients with exogenous <em>Candida</em> endophthalmitis require aggressive multimodality therapy to control infection and preserve vision. We use the following approach:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intraocular antifungal therapy</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with exogenous <em>Candida</em> endophthalmitis with vitreous involvement, we recommend intravitreal injection of an antifungal agent (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>); either <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (5 or 10 mcg in 0.1 mL sterile water) or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> (100 mcg in 0.1 mL sterile water or normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) for all cases. Intravitreal injections may be repeated, usually after two days or more. We recommend vitrectomy in cases with marked vitritis or in cases failing intravitreal injections (plus adjunctive systemic therapy). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with exogenous <em>Candida</em> ocular infection with primarily aqueous involvement, we recommend intracameral injection of an antifungal agent (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>); either <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (5 mcg in 0.1 mL sterile water) or <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> (50 mcg in 0.1 mL sterile water or normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) may be used. In addition, in patients with exogenous <em>Candida</em> endophthalmitis resulting from <em>Candida</em> keratitis, we also recommend administration of voriconazole eyedrops (1 percent) (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). Some patients with endophthalmitis resulting from severe <em>Candida</em> keratitis may also require corneal transplantation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Systemic antifungal therapy</strong> – For all patients with exogenous <em>Candida</em> endophthalmitis, we recommend systemic azole therapy targeted to the susceptibility of the pathogen (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>); many patients can receive <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, but some require <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Foreign body management</strong> – All foreign bodies (eg, intraocular lenses placed during cataract surgery) should be surgically removed if primary treatment fails. (See <a class="local">'Approach to treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endogenous endophthalmitis</strong> – The management of endogenous endophthalmitis caused by <em>Candida </em>species and endophthalmitis caused by molds is presented separately. (See  <a class="medical medical_review" href="/z/d/html/2446.html" rel="external">"Treatment of endogenous endophthalmitis and chorioretinitis due to Candida species"</a> and  <a class="medical medical_review" href="/z/d/html/16205.html" rel="external">"Treatment of endophthalmitis due to molds"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a class="nounderline abstract_t">Thiel MA, Zinkernagel AS, Burhenne J, et al. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother 2007; 51:239.</a></li><li><a class="nounderline abstract_t">Pflugfelder SC, Flynn HW Jr, Zwickey TA, et al. Exogenous fungal endophthalmitis. Ophthalmology 1988; 95:19.</a></li><li><a class="nounderline abstract_t">Kuriakose T, Kothari M, Paul P, et al. Intracameral amphotericin B injection in the management of deep keratomycosis. Cornea 2002; 21:653.</a></li><li><a class="nounderline abstract_t">Yoon KC, Jeong IY, Im SK, et al. Therapeutic effect of intracameral amphotericin B injection in the treatment of fungal keratitis. Cornea 2007; 26:814.</a></li><li><a class="nounderline abstract_t">Wykoff CC, Flynn HW Jr, Miller D, et al. Exogenous fungal endophthalmitis: microbiology and clinical outcomes. Ophthalmology 2008; 115:1501.</a></li><li><a class="nounderline abstract_t">Shen YC, Wang CY, Tsai HY, Lee HN. Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis. Am J Ophthalmol 2010; 149:916.</a></li><li><a class="nounderline abstract_t">Lin RC, Sanduja N, Hariprasad SM. Successful treatment of postoperative fungal endophthalmitis using intravitreal and intracameral voriconazole. J Ocul Pharmacol Ther 2008; 24:245.</a></li><li><a class="nounderline abstract_t">Shen YC, Wang MY, Wang CY, et al. Pharmacokinetics of intracameral voriconazole injection. Antimicrob Agents Chemother 2009; 53:2156.</a></li><li><a class="nounderline abstract_t">Vemulakonda GA, Hariprasad SM, Mieler WF, et al. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch Ophthalmol 2008; 126:18.</a></li><li><a class="nounderline abstract_t">Goyal J, Fernandes M, Shah SG. Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis. Am J Ophthalmol 2010; 150:939; author reply 939.</a></li><li><a class="nounderline abstract_t">Kernt M, Neubauer AS, De Kaspar HM, Kampik A. Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis. Retina 2009; 29:362.</a></li><li><a class="nounderline abstract_t">Palioura S, Relhan N, Leung E, et al. Delayed-onset Candida parapsilosis cornea tunnel infection and endophthalmitis after cataract surgery: Histopathology and clinical course. Am J Ophthalmol Case Rep 2018; 11:109.</a></li><li><a class="nounderline abstract_t">Kauffman CA, Bradley SF, Vine AK. Candida endophthalmitis associated with intraocular lens implantation: efficacy of fluconazole therapy. Mycoses 1993; 36:13.</a></li><li><a class="nounderline abstract_t">Tod M, Lortholary O, Padoin C, Chaine G. Intravenous penetration of fluconazole during endophthalmitis. Clin Microbiol Infect 1997; 3:143.</a></li><li><a class="nounderline abstract_t">Urbak SF, Degn T. Fluconazole in the management of fungal ocular infections. Ophthalmologica 1994; 208:147.</a></li><li><a class="nounderline abstract_t">Park SS, D'Amico DJ, Paton B, Baker AS. Treatment of exogenous Candida endophthalmitis in rabbits with oral fluconazole. Antimicrob Agents Chemother 1995; 39:958.</a></li><li><a class="nounderline abstract_t">Kim JE, Perkins SL, Harris GJ. Voriconazole treatment of fungal scleritis and epibulbar abscess resulting from scleral buckle infection. Arch Ophthalmol 2003; 121:735.</a></li><li><a class="nounderline abstract_t">Breit SM, Hariprasad SM, Mieler WF, et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005; 139:135.</a></li><li><a class="nounderline abstract_t">GREEN WR, BENNETT JE, GOOS RD. OCULAR PENETRATION OF AMPHOTERICIN B: A REPORT OF LABORATORY STUDIES AND A CASE REPORT OF POSTSURGICAL CEPHALOSPORIUM ENDOPHTHALMITIS. Arch Ophthalmol 1965; 73:769.</a></li><li><a class="nounderline abstract_t">Stern WH, Tamura E, Jacobs RA, et al. Epidemic postsurgical Candida parapsilosis endophthalmitis. Clinical findings and management of 15 consecutive cases. Ophthalmology 1985; 92:1701.</a></li><li><a class="nounderline abstract_t">Yang YS. Results of extensive surgical treatment of seven consecutive cases of postoperative fungal endophthalmitis. Korean J Ophthalmol 2009; 23:159.</a></li></ol></div><div id="topicVersionRevision">Topic 16220 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17060517" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3257818" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Exogenous fungal endophthalmitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12352080" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Intracameral amphotericin B injection in the management of deep keratomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17667615" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Therapeutic effect of intracameral amphotericin B injection in the treatment of fungal keratitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18486220" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Exogenous fungal endophthalmitis: microbiology and clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20434131" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18321199" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Successful treatment of postoperative fungal endophthalmitis using intravitreal and intracameral voriconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19258273" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pharmacokinetics of intracameral voriconazole injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18195213" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21094710" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18997637" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29998210" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Delayed-onset Candida parapsilosis cornea tunnel infection and endophthalmitis after cataract surgery: Histopathology and clinical course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8316256" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Candida endophthalmitis associated with intraocular lens implantation: efficacy of fluconazole therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11864094" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Intravenous penetration of fluconazole during endophthalmitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8065700" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fluconazole in the management of fungal ocular infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7786003" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Treatment of exogenous Candida endophthalmitis in rabbits with oral fluconazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12742860" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Voriconazole treatment of fungal scleritis and epibulbar abscess resulting from scleral buckle infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15652837" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Management of endogenous fungal endophthalmitis with voriconazole and caspofungin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14302507" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : OCULAR PENETRATION OF AMPHOTERICIN B: A REPORT OF LABORATORY STUDIES AND A CASE REPORT OF POSTSURGICAL CEPHALOSPORIUM ENDOPHTHALMITIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4088622" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Epidemic postsurgical Candida parapsilosis endophthalmitis. Clinical findings and management of 15 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19794941" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Results of extensive surgical treatment of seven consecutive cases of postoperative fungal endophthalmitis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
